Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That is not fully true. Material in many scientific handbooks do not provide or are not intended to provide a road map for experiment replication. They are sources of reference material for standardization, scientific advancement and product development in ways that facilitate knowledge building and consistent practices.
I have not read the latest CRC publication, but I have read the previous one where the science was explained and the fundamentals and legitimacy of NNVC therapeutic advancements were delineated (ref - CRC publication Bionanotechnology II ISBN -10: 143980463X).
Have a great day!
HS
So what is this about a rumor?
While my rumor detector is peaking, I am not getting a clear signal.
I suspect either they have started, or are starting human trials. Or Japan or others are coming through.
I still love the idea that late this year the patients undergoing trials will actually be able to communicate with doctors, unlike that with the primate study.
best of luck to all longs and wishing them the best of good buys!
HS
Nice to see a second CRC publication! Yes, the book costs a lot. Yes, it is not for general public consumption or for stock junkies either.
In recognizing a long time ago that the scientific community needed to have good strong reference material, the CRC (Chemical Rubber Company)press started the ball rolling with the world-wide leading CRC Handbook of Chemistry and Physics.
They do not publish trash of any kind. They publish text and handbooks for scientist and engineers to use as valid highly useful reference material. I own several expensive CRC handbooks and I can say they have served me very well over the years. They are an excellent source of scientific and technical information applicable to research and product development. They have often been called the Bibles of Science and Technology!
NNVC Technology was also published in an earlier bioengineering CRC Book as well.
Wishing all the best of good buys!
HS
NNVC's New Year should have some interesting days.
I hope the only sideline is for the topicals. NNVC keeps their cash burn quite reasonable. As such, what a boost it would be to see a possible nearer term revenue stream. Topicals also have a lot more possible simpler partnerships that could help in that end.
whatever happened to _______?
Florey Institute - Extreme Top Notch World Leaders in Neuroscience Research
The Florey Institute of Neuroscience and Mental Health is one of the world’s leading brain research centers. Florey employs more than 500 staff and educate in excess of 100 post-graduate students each year. Our scientists comprise the largest neuroscience research team in Australia.
Teams work on a range of serious diseases including stroke, epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Huntington’s disease, motor neuron disease, traumatic brain and spinal cord injury, depression, schizophrenia, mental illness and addiction. We are world leaders in imaging technology, stroke rehabilitation and epidemiological studies.
Over the past 10 years research of the brain and its diseases has gained considerable momentum internationally. Many scientific and technological advancements have been made, and much of Florey's work has been center stage. They are a hive of activity with researchers coming from around the globe to work at the Florey.
State and Federal Governments, major philanthropic foundations and many generous private benefactors have recognized the importance of neuroscience as the final frontier in medical research, and they are helping Florey and its partners build two state-of-the-art research facilities, one at the University of Melbourne in Parkville and the other at the Austin Hospital in Heidelberg costing in excess of $200 million.
ISCO could not have picked a better partner to move their Parkinson therapeutics through the human studies to quickly benefit the worlds's population suffering or those that would be going to suffer from Parkinsons.
ISCO continuously marching forward.
2016 should be interesting. Actual human test results will be coming! I know the primate study needed to reach this stage achieved good results. But nothing compares to being able to actively interview the patient.
I am confident the human results will be positive, but if very strongly positive, wow, look out.
One thing I have not liked about this company is the cash burn and how close it always is to having zero cash. Yet, the thing that has always impressed me is the achieve a good part of what they say they are doing.
They say they are going to make a side business to help fund the research cash burn; they do it. Not only do they do it, but is shows steady growth and product expansion.
They say they will partner with a Japanese pharma and they do for shared product interests.
They say they will work with the leading university on Parkinsons and perform the needed primate studies to allow human studies; and they do it with good results.
They say they will go to Australia to reduce cost and time to market versus the FDA, a successful path for others; and they do it. Not only do they do it, but get the go-ahead from the authorities to proceed in almost record time. What does that mean, it means real human results are here in 2016. Place your bets on what you think the human patients will say. That is the bottom line!
I am not saying to buy, sell or hold, but this company is quite interesting to say the least. At a 14 million market cap, even if things failed eventually, it is hard not to fathom a 200-400 million market cap at some point in all the chaos and activity. Is that a 10+ banger, maybe. Lets hope for all those longs.
He has an inside view alright. While Flucide might be the eventual big winner, watch topical agents be the first to market.
HS
Still long on NNVC
While I wish share prices had not reached these levels, I also think these lower share prices and the overall market volatility, could actually help force company focus and milestone attainment.
In this environment it will be harder for them to raise new cash at a good deal like they have been able to do so far. The biggest disappointment I have had with NNVC’s development progress is the missing of stated timelines, often by their shifting of gears as a result of contemporary viral infection outbreaks or other distractors. Other distractors that were actually good test results on other viral types!
What is remarkable, regardless of the timeline, is what they have achieved with the total investment so far. NNVC is actually close to the best in the biotech industry at developing therapeutics with such good efficacy results at the lowest absolute cost of development overall. Yet, distractors have added up and blurred product development focus.
In an environment like we are entering for NNVC and the markets in general they may need to take what they have, still about 2 years funding on hand, make sure they have a stable path forward. This is the first time something I would have called a distractor once again, the anti-herpesvirus work, is now a plus. I had hoped they took this path earlier. It may prove to be a great financial stabilizer for the company. I suspect this could also be pushed a little by Dr. Boniuk on the BOD and potentially why he is such a big insider buyer.
Topical therapeutics are indeed far far far more easily brought to market. 90% or more less red tape to start with! If suitable, they should look for a partner to produce the creams and other carriers, to allow getting to the market as soon as possible. That would give them some revenues to fund expansion and development, plus good experience as well. It would also bring back investor confidence in that we would start to see a business taking shape underneath the great potential the Nanovircides have to offer.
Best of luck to all. A good friend’s wife just passed away from ovarian cancer. It was not a good scene. Enjoy every day and every moment you can. In the end, it is not the investment gains one made, or objects they acquired that hold any true value. All we really have is the present and all that really matters is our feelings. Regardless of what you think about NNVC, I am glad there are people out there that try to develop products that help reduce suffering. Which is better, to develop a drug that doesn’t make it or a phone app that doesn’t make it, or ones that do and/or show the way.
HS
Yes, but that showed some weakness as of late. Hopefully not a sign of dwindling sales. I assumed a 1:150 RS, but it needed to be coupled with an equity offering/purchase that captured around $5/share so the could at least raise 5 million with significant dilution to us. Their burn rate has simply been too high. If they can make their stand alone products increase sales again and reduce other operational cost to make a small profit, they could then gain some real financial footing that would be supportive and not a negative. Even if they delayed trials, they need to get on some realistically sustainable budget with predictable health over a future time span of at least 24 months. If they do that, this will become a screaming buy! Until then, it could just go away, which would be extremely sad, not just for me and you, but for humanity in general.
Not sure about any bottom. They have announced a R/S coming, then went silent about it. Their finances (out of cash) and burn rate (quite high) is out of wack. They need to develop a funding strategy that is longer than 30 to 60 days. Preferably a 2 year funding strategy. Then you will see higher movement from whatever that drops them to. It is a shame because they have a super product to develop and a current product being sold.
HS
ISCO Please follow through on your announced reverse split or not.
Above all, develop a 24 month minimum funding strategy that includes RS or whatever else.
ISCO has some good technology, some good products and good potential. Until an outstanding stock and funding strategy is made more clear and reasonably doable, even news of trails starting in Australia, wont support coming off these lows.
The only news that would work alone would be a buyout or a sudden dramatic increase in their peripheral product sales to cover funding needs.
It is frustrating seeing good and hopeful technologies get squelched in the development stage from funding and regulation fatigue.
HS
I just don't know. I am not sure it is going to 1 cent, but if we have the reverse split that they said to prepare for, then I could see a split adjusted dilution low of about 2 or 3 cents for a short period after the R/S.
I wish I had that old crystal ball or better yet, a magic lamp!
HS
Looks like they wont have a CFO for a while after Jay leaves. Too bad. This company has a real product and a real shot at significant therapeutics.
Cant see investing more until the R/S issue and longer term finances are settled. Something to keep an eye on though.
HS
Some reports have suggested the facility is not fully equipped/operational yet. If so, scale-up activities may not have been investigated too far as of yet. Scale-up is a difficult process at times. I am not sure what sort of exact issues they might be having with it and/or if they are truly serious or not. Even if they had a problem, multiple smaller set-ups could potentially generate enough for final tox and trials.
If they are having an issue with scale-up, I would love to attend a meeting or be the 'fly on the wall'. Not that I could guarantee I could help, but it would be fun to review and think about. Scale-up of a chemical/mechanical process is quite interesting, especially in the fluid mixing and contacting arena. Maintaining equivalent power per unit volumes, torque per unit volumes, vessel geometry ratios, etc., is not always appropriate. Localized shear rates and micro-vorticie dissipation rates may interrupt stable attachment mechanisms. It is both a science and an art to get a handle on. Some might be surprised just how much of a trial and error art it is to produce effective scale-up procedures. Some might also think that in this day and age, these things should be well known, and be surprised to find out just how hands on trial and error it still needs to be.
Wishing all the best of good buys...
HS
Nice details in the PR. Also nice see an effort to get a topical out. Topical therapeutics don't require all the intense FDA requirements to get to market. It would be good for them to get to some revenue stream with a topical. That would be a worth while effort. Investigating new/other viral strains is not at this time. More important to get Flucide to clinical.
I am still confused on the number of shares traded in a day being a significant portion of, or near, or at, or even above the outstanding number of shares. Someone please enlighten me.
I agree.
If they used the word 'specific' instead of "certain" or also replaced the word "testing" with "scientific analytic procedures" or the word "infected" with "diseased" or "superior" with "excellent", that might have pacified them, but I doubt it.
No, I doubt they are paying much attention. But it is not scam BS research work either. It is real research and test results from an independent reputable medical researcher, regardless of how you or others want to portray it.
I have been by NEOMED. Dr. Rosenthal does great thorough work there. Top Notch.
I wish I lived closer to them. I would like to stop by, sign a confidentiality agreement and discuss what any of their scale up issues are. I might suspect if they are having a problem it could be related to micro vorticies in fluid mixing. Scale-up of fluid mixing is one of the areas I have dealt with. However, that might not be it at all, if anything.
Wishing all the best of good buys.
HS
Reading through the report that came today in the mail I find the going concern statement stronger than ever these days. What a shame, because these guys really have something. But I have seen companies with good technology get put down many times over my 40 years of investing. Thye may be able to eventually break out of this dilution loop they are in, but unfortunately I think we will eventually see another 80% loss from here for the common stock shareholders before the dilution scenario can turn around.
I might have missed it, but did anyone see any discussion on the reverse split, or have any information on its impending potential and magnitude?
Best of luck to all trying to move their portfolios forward instead of backward or subject to peril.
Wishing all the best of good buys....
HS
I agree. The nearly fully depleted cash, high cash burn rate, also to get higher if/when trials begin and the REVERSE split is hanging over this in a very strong way. They annonuced a reverse split coming quite a while ago, best to get it over with and then maybe it can more forward in some meaningful way. Especially if they couple the reverse split with a move to a bigger board where they can have better access to investment cash.
Recent drop has been more a result of the negative side of being on the bigger boards where you become part of biotech and/or sector fund than a particular failure on part of an individual company.
They are great initially due to buy-ins, but then allow the negative influence when the sectors are being sold off.
Flucide will make or break the company. If you are in for the long run on NNVC, that final outcome is the point you are looking for. If your negative or short on the company, well then that is just a position you hold that is not necessarily tied to an event.
Best of luck to all NNVC longs.
HS
You mean far less than 9 bucks
Thanks Mr Chip for the extended info.
I have been following this since the ADSX days. Now that is some total effective R/S.
HS
Whats up with the share structure post R/S? Trading volume seems higher than outstanding. Is their naked shorting going on somehow.
HS
NNVC to facilitate transplants.
Australian Clinical Study
ISCO is a developmental biotech company with revenues!
Now they today announce initial phases of starting a clinical study in Australia.. Thye are showing steady movement forward on their goals. Nice to see. I hope the revenue side continues to grow as has been the case. It may eventually pay a significant share of the development costs.
Good to see the positive insider activity, the recent submittals and the preliminary TOX results....all positive.
Wishing most the best of good buys!
HS
Ya, the CNBC morons just introduced them as Nanovaricity!
Idiots that CNBC bunch are!
CNBC recongized Nanoviricides for Ebola treatments
http://www.cnbc.com/id/101887615?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=101887615
Ebola is a side-show. Dengue, which can be similar is not.
Influenza is the key and path forward of focus.
Look for firming guidance.
I am so glad perfection does not get boring!
I am perfect in all regards!
and I totally agree with your assessment of yourself and NNVC!
I am certainly down on this one, but the osaka based Rohto Pharmaceutical tie might get interesting. Skin Care contributes to 61.3% of their revenues.
B&W Buys MAGTEC...good move for support of baseline products and for diversification into other markets!
This is a positive for B&W.
Any truth to this thing with Pfizer?
While I think Pfizer (PFE) would be smart to work with them or try to be hooked in as things move along, I have my doubts to the nature of this net intel/rumor.
http://www.blognation.com/post/3747063/http://sierraworldequityreview.blogspot.com/2014/05/pfizer-pfe-looks-to-partner-with.html
More like 9 years of successes when viewed without bias.
The Street Lists NNVC as a stock under 10 with BREAKOUT mode potential today.
www.thestreet.com/story/12698350/1/3-under-10-stocks-triggering-breakout-trades.html?puc=yahoo&cm_ven=YAHOO
I am not sure who Gorden is, but I saw on another
site that Gorden was high on NNVC. Makes sense to me.
Is Viroclinics working on the MERS tests? While a few less knowledgeable poo poo animal testing, if NNVC shows good results against MERS at another set of highly qualified independent labs like they have for other viral types, their goal of demonstrating viable, effective, omnipotent anti-viral theraputics will be un matched in the world.
Go NNVC
Go Gorden, rumor has it you are never wrong!
BULLSHIT!
I agree. Old crap rehashed in a low budget way. It is sad that crap like that can actually influence a stock. What BS.
Oh well, we just have to grinn and bare the nonsence until they do make the progress milestone that will get noticed, the IND.
NNVC, go overseas if needed, get it done and shut these idiots up.
In the meantime, it is just more of the concerted effort that repeats the same crap to try and lower the price again.